发明名称 |
Treatment with gemcitabine and an EGFR-inhibitor |
摘要 |
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and gemcitabine combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva(TM)). |
申请公布号 |
ZA200610049(B) |
申请公布日期 |
2008.06.25 |
申请号 |
ZA20060010049 |
申请日期 |
2006.11.30 |
申请人 |
F. HOFFMANN-LA ROCHE AG. |
发明人 |
HIGGINS, BRIAN;KOLINSKY, KENNETH |
分类号 |
A61K;A61K31/4706;A61K31/498;A61K31/513;A61K31/517;A61K31/519;A61K31/5377;A61K31/7072;A61P |
主分类号 |
A61K |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|